# Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

> **NCT01650350** · PHASE2 · TERMINATED · sponsor: **Brown University** · enrollment: 7 (actual)

## Conditions studied

- Melanoma
- Prostate Cancer
- Renal Cancer

## Interventions

- **DRUG:** Naltrexone

## Key facts

- **NCT ID:** NCT01650350
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study stopped 10/24/13 secondary to lack of patients/slow enrollment
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650350, "Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01650350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*